compani
post-wclc po de-risk
longer durat benefit
higher po data de-risk durat benefit
follow data present investor call updat posit lung cancer
data wclc modestli rais po higher sale forecast
reflect higher weighted-averag probability-to-market
assumpt across tumor type vs prior follow support
registr lung data longer durat treatment assumpt vs
mo prior conserv estimate base lower end confid
interv ci progression-fre surviv median ci
given data immatur updat forecast vs
prior risk-adjust sale assum peak ret-
fusion lung market share compar consensu pre-wclc estimate
plan present thyroid data esmo sept oct maintain
neutral balanc posit wclc data lack needl move catalyst
competitor headwind limit upsid consensu estimate
takeaway confer call
highlight regulatori timelin plan file us nda end
eu earli japan/china current timelin put
potenti acceler us approv commerci ramp hope
approv along partnership major companion diagnost
provid improv ret test beyond current oncolog practic current
use test screen ret fusion believ ret test strong
uptak stop short guid time-frame achiev broad-bas test
although management cite encourag uptak test alk/egfr mutat lung
cancer competit posit emphas data stand given
robust divers data rel larg patient dataset heavili pre-treat
patient to-dat key point competit differenti believ
becom new standard-of-car ret-fus lung cancer vs bpmc blu-
drug may requir addit screen possibl transfus
cytopenia side effect without ad efficaci benefit continu page
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
wclc world confer lung cancer
esmo european societi medic
ret rearrang transfect
timestamp septemb edtcr eli lilli compani
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani septemb
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough target
drug resist base in-hous data believ neither work
patient develop acquir resist ret inhibitor thu limit
opportun ret-inhibitor re-treat resist front continu
explor next-gen ret-inhibitor treat patient acquir resist phase
studi beyond acceler approv path plan run two studi
set -- one studi compar vs physician choic chemo chemo
keytruda lung cancer nsclc anoth studi compar vs cabozantinib
vandetanib thyroid cancer mtc
compani septemb
compani
price object po base blend averag discount
cash flow dcf multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani septemb
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani septemb
